Resmed (RSMDF) EBITDA Margin (2009 - 2026)
Resmed's (RSMDF) quarterly EBITDA Margin came in at 30.66% in Q2 2026, down 306.0% on a YoY basis from 14.88% in Q2 2025, and down 12.2% quarter-over-quarter from 34.92% in Q1 2026.
Powered by 
Analysis
Resmed (RSMDF) EBITDA Margin (2009 - 2026) Analysis & Trends
Resmed (RSMDF) has reported EBITDA Margin for 18 consecutive years, with 30.66% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBITDA Margin fell 306.0% year-over-year to 30.66%; the trailing twelve-month figure through Jun 2026 stood at 33.37% (up 62.0% YoY), and the FY2026 full-year result was 35.19%, up 27.0% from the prior year.
- EBITDA Margin retreated to 30.66% in Q2 2026 per RSMDF's latest filing, from 34.92% in the prior quarter.
- Across five years, EBITDA Margin topped out at 34.92% in Q1 2026 and bottomed at 23.66% in Q4 2023.
- Historically, EBITDA Margin has averaged 29.97% across 5 years, with a median of 30.91% in 2024.
- The sharpest annual moves came in 2023 and 2024: EBITDA Margin tumbled 345 bps in 2023, then jumped 889 bps in 2024.
- Over 5 years, EBITDA Margin stood at 27.1% in 2022, then fell by 13 bps to 23.66% in 2023, then surged by 38 bps to 32.54% in 2024, then grew by 6 bps to 34.56% in 2025, then decreased by 11 bps to 30.66% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 30.66%, 34.92%, and 34.56% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 184.06 Bn | 178.46 Bn | 7.27 Bn | 13.44% |
| 2 | Intuitive Surgical | 124.29 Bn | 119.08 Bn | 1.96 Bn | 33.60% |
| 3 | Medtronic | 118.26 Bn | 109.44 Bn | 6.34 Bn | 18.08% |
| 4 | Stryker | 104.56 Bn | 101.08 Bn | 4.50 Bn | 25.18% |
| 5 | Boston Scientific | 66.33 Bn | 65.79 Bn | 3.85 Bn | 21.65% |
| 6 | Edwards Lifesciences | 49.62 Bn | 45.37 Bn | 1.35 Bn | 29.48% |
| 7 | Alcon | 33.94 Bn | 32.48 Bn | 1.68 Bn | 0.40% |
| 8 | Dexcom | 32.18 Bn | 30.23 Bn | 830.00 Mn | 24.33% |
| 9 | Steris | 21.14 Bn | 20.65 Bn | 684.20 Mn | 19.15% |
| 10 | Resmed | 3.54 Bn | 2.07 Bn | 861.22 Mn | 30.66% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 30.66% |
| Mar 31, 2026 | 34.92% |
| Dec 31, 2025 | 34.56% |
| Sep 30, 2025 | 33.43% |
| Jun 30, 2025 | 33.72% |
| Mar 31, 2025 | 33.00% |
| Dec 31, 2024 | 32.54% |
| Sep 30, 2024 | 31.63% |
| Jun 30, 2024 | 31.17% |
| Mar 31, 2024 | 31.29% |
| Dec 31, 2023 | 23.66% |
| Sep 30, 2023 | 26.22% |
| Jun 30, 2023 | 24.53% |
| Mar 31, 2023 | 26.92% |
| Dec 31, 2022 | 27.10% |
| Sep 30, 2022 | 29.02% |
| Jun 30, 2022 | 27.92% |
| Mar 31, 2022 | 27.10% |
| Dec 31, 2021 | 27.79% |
| Sep 30, 2021 | 28.97% |